Advertisement

Impact of Solid-State Characteristics to the Physical Stability of Drug Substance and Drug Product

  • Yushen Guo

Abstract

In the drug development and commercialization process, the acceptable stability of the drug substance and drug product is one of the basic requirements for clinical studies, regulatory approval, and marketing. The stability of a drug product is related not only to the intrinsic chemical stability of the drug molecule, but also to the physical forms, manufacturing processes, interactions among formulation components, container closure systems, and storage conditions. In the past two decades, there has been a significant increase in the mechanistic understanding of the solid-state characteristics of pharmaceutical systems, along with the advancement of analytical techniques. Physical stability, as one of the quality attributes of drug products, should be designed into the formulation components and critical manufacturing steps using the Quality by Design (QbD) strategy to achieve intended shelf-life and product performance. In this Chapter, the major physical stability attributes of drug dosage forms are discussed with focus on the effects of solid-state properties of drug substance and manufacturing processes. The solid-state physical changes involving polymorphs, hydrates, amorphous forms, and the effect of water are highlighted.

Keywords

Dosage Form Drug Product Drug Substance Physical Stability Amorphous Form 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Tingstad JE (1964) Physical stability testing of pharmaceuticals. J Pharm Sci 53:955–962.CrossRefPubMedGoogle Scholar
  2. 2.
    Perlia X (1967) Stability and stabilization of drugs. II. Physical viewpoints. Pharm Acta Helv 42:265–302.PubMedGoogle Scholar
  3. 3.
    ICH Guideline Q6A (1999) Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances.Google Scholar
  4. 4.
    ICH Guideline Q1A (2001) Stability Testing of New Drug Substance and Products.Google Scholar
  5. 5.
    Pearlman R, Wang YJ (1996) Formulation, Characterization, and Stability of Protein Drugs: Case Histories. Plenum Publishing Corporation, New York.Google Scholar
  6. 6.
    Brange J (2000) Physical stability of proteins. In: Frokjaer S, Hovgaard L (eds) Pharmaceutical Formulation Development of Peptides and Proteins. Taylor & Francis, London and New York, pp 89–112.Google Scholar
  7. 7.
    Childs SL, Chyall LJ, Dunlap JT., Smolenskaya VN, Stahley BC, Stahly GP (2004) Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids. J Am Chem Soc 126:13335–13342.CrossRefPubMedGoogle Scholar
  8. 8.
    Grant DJW (1999) Theory and origin of polymorphism. In: Brittain HG (ed) Polymorphism in Pharmaceutical Solids. Marcel Dekker, Inc., New York, pp 1–34.Google Scholar
  9. 9.
    Brittain HG, Fiese EF (1999) Effect of pharmaceutical processing on drug polymorphs and solvates. In: Brittain HG (ed) Polymorphism in Pharmaceutical Solids. Marcel Dekker, Inc., New York, pp 331–362.Google Scholar
  10. 10.
    Variankaval N, Sheth AR (2007) Physical stability of crystal forms – implications in drug development. Am Pharm Rev 10: 96–101.Google Scholar
  11. 11.
    Raw AS, Furness MS, Gill DS, Adams, RC, Holcombe Jr FO, Yu LX (2004) Regulatory consideration of pharmaceutical solid polymorphism in abbreviated new drug applications (ANDAs). Adv Drug Deliv Rev 56:397–414.CrossRefPubMedGoogle Scholar
  12. 12.
    FDA Guideline (1987) Guideline for submitting supporting documentation in drug application for the manufacture of drug substances.Google Scholar
  13. 13.
    Newman AW, Byrn SR (2004) Solid-state analysis of the active pharmaceutical ingredient in drug products. Drug Discov Today 8:898–905.CrossRefGoogle Scholar
  14. 14.
    Stephenson GA, Forbes RA, Reutzel-Edens SM (2001) Characterization of the solid state: quantitative issues. Adv Drug Deliv Rev 48:67–90.CrossRefPubMedGoogle Scholar
  15. 15.
    Shah B, Kakumanu VK, Bansal AK (2006) Analytical techniques for quantification of amorphous/crystalline phases in pharmaceutical solids. J Pharm Sci 95:1641–1665.CrossRefPubMedGoogle Scholar
  16. 16.
    Grunenberg A, Henck J-O, Siesler, HW (1996) Theoretical derivation and practical application of energy/temperature diagrams as an instrument in preformulation studies of polymorphic drug substances. Int J Pharm 129:147–158.CrossRefGoogle Scholar
  17. 17.
    Byrn S, Pfeiffer R, Ganey M, Hoiberg C, Poochikian G (1995) Pharmaceutical solids: a strategic approach to regulatory considerations. Pharm Res 12:945–954.CrossRefPubMedGoogle Scholar
  18. 18.
    Morissette SL, Soukasene S, Levinson D, Cima MJ, Almarsson Ö (2003) Elucidation of crystal form diversity of the HIV protease inhibitor ritonavir by high-throughput crystallization. Proc Natl Acad Sci USA 100:2180–2184.Google Scholar
  19. 19.
    Jones W, Motherwell WDS, Trask AV (2006) Pharmaceutical cocrystals: an emerging approach to physical property enhancement. MRS Bull 31:875–879.Google Scholar
  20. 20.
    Trask AV, Motherwell WDS, Jones W (2006) Physical stability enhancement of theophylline via cocrystallization. Int J Pharm 320:114–123.CrossRefPubMedGoogle Scholar
  21. 21.
    Reutzel SM, Russell VA (1998) Origins of the unusual hygroscopicity observed in LY297802 tartrate. J Pharm Sci 87:1568–1571.CrossRefPubMedGoogle Scholar
  22. 22.
    Dalton CR, Clas S-D, Singh J, Khougaz K, Bilbeisi R (2005) Investigating the hydrate conversion propensity of different etoricoxib lots. J Pharm Sci 95:56–69.CrossRefGoogle Scholar
  23. 23.
    Han J, Suryanarayanan R (1999) A method for the rapid evaluation of the physical stability of pharmaceutical hydrates. Thermochimi Acta 329:163–170.CrossRefGoogle Scholar
  24. 24.
    Sacchetti, M (2004) Determining the relative physical stability of anhydrous and hydrous crystal forms of GW2016. Int J Pharm 273:195–202.CrossRefPubMedGoogle Scholar
  25. 25.
    Kojima T, Yamauchi Y, Onoue S, Tsuda Y (2008) Evaluation of hydrate formation of a pharmaceutical solid by using diffuse reflectance infrared Fourier-transform spectroscopy. J Pharm Biomed Anal 46:788–791.CrossRefPubMedGoogle Scholar
  26. 26.
    Higgins J, Arrivo SM, Reed RA (2003) Approach to the determination of hydrate form conversions of drug compounds and solid dosage forms by near-infrared spectroscopy. J Pharm Sci 92:2303–2316.CrossRefPubMedGoogle Scholar
  27. 27.
    Zeitler JA, Kogermann K, Rantanen J, Rades T, Taday PF, Pepper M, Aaltonen J, Strachan CJ (2007) Drug hydrate systems and dehydration processes studied by terahertz pulsed spectroscopy. Int J Pharm 334:78–84.CrossRefPubMedGoogle Scholar
  28. 28.
    Cypes SH, Wenslow RM, Thomas SM, Chen AM, Doerwart JG, Corte JR, Kaba M (2004) Drying an organic monohydrate: crystal form instabilities and a factory-scale drying scheme to ensure monohydrate preservation. Org Process Res Dev 8:576–582.CrossRefGoogle Scholar
  29. 29.
    Hancock BC, Zografi G (1997) Characteristics and significance of amorphous state in pharmaceutical systems. J Pharm Sci 86:1–12.CrossRefPubMedGoogle Scholar
  30. 30.
    Andronis V, Zografi G (2000) Crystal nucleation and growth of indomethacin polymorphs from the amorphous state. J Non-Cryst Solids 271:236–248.CrossRefGoogle Scholar
  31. 31.
    Yonemochi E, Hoshino T, Yoshihashi Y, Terada K (2005) Evaluation of the physical stability and local crystallization of amorphous terfenadine using XRD-DSC and micro-TA. Thermochim Acta 432:70–75.CrossRefGoogle Scholar
  32. 32.
    Marsac PJ, Konno H, Taylor LS (2006) A comparison of the physical stability of amorphous felodipine and nifedipine systems. Pharm Res 23:2306–2316.CrossRefPubMedGoogle Scholar
  33. 33.
    Serajuddin ATM (1999) Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 88:1058–1066.CrossRefPubMedGoogle Scholar
  34. 34.
    Huang J, Wigent RJ, Schwartz JB (2008) Drug-polymer interaction and its significance on the physical stability of nifedipine amorphous dispersion in microparticles of an ammonio methacrylate copolymer and ethylcellulose binary blend. J Pharm Sci 97:251–262.CrossRefPubMedGoogle Scholar
  35. 35.
    Miyazaki T, Yoshioka S, Aso Y (2006) Physical stability of amorphous acetanilide derivatives improved by polymer excipients. Chem Pharm Bull 54:1207–1210.CrossRefPubMedGoogle Scholar
  36. 36.
    Mallick S, Pattnaik S, Swain K, De PK, Saha A, Ghoshal G, Mondal A (2008) Formation of physically stable amorphous phase of ibuprofen by solid state milling with kaolin. Eur J Pharm Biopharm 68:346–351.CrossRefPubMedGoogle Scholar
  37. 37.
    Ahlneck C, Zografi G (1990) The molecular basis for moisture effects on the physical and chemical stability of drugs in the solid-state. Int J Pharm 62:87–95.CrossRefGoogle Scholar
  38. 38.
    Shalaev EY, Zografi G (1996) How does residual water affect the solid-state degradation of drugs in the amorphous state? J Pharm Sci 85:1137–1141.CrossRefPubMedGoogle Scholar
  39. 39.
    Tong P, Zografi G (2004) Effects of water vapor absorption on the physical and chemical stability of amorphous sodium indomethacin. AAPS Pharm Sci Technol 5(2):Article 26.Google Scholar
  40. 40.
    Lechuga-Ballesteros D, Miller DP (2003) Microcalorimetric measurement of the interactions between water vapor and amorphous pharmaceutical solids. Pharm Res 20:308–318.CrossRefPubMedGoogle Scholar
  41. 41.
    Begat P, Young PM, Edge S, Kaerger, JS, Price R (2003) The effect of mechanical processing on surface stability of pharmaceutical powders: visualization by atomic force microscopy. J Pharm Sci 92:611–620.CrossRefPubMedGoogle Scholar
  42. 42.
    Ohta M, Buckton G (2004) Determination of the change in surface energetics of cefditoren pivoxil as a consequence of processing induced disorder and equilibration to different relative humidities. Int J Pharm 269:81–88.CrossRefPubMedGoogle Scholar
  43. 43.
    Yokoi Y, Yonemochi E, Terada K (2005) Measurement of surface glass transition temperature of amorphous cefditoren pivoxil granules by inverse gas chromatography. J Drug Deliv Sci Techol 15:439–442.Google Scholar
  44. 44.
    Paul IC. Curtin DY (1973) Thermally induced organic reactions in the solid state. Acc Chem Res 6:217–225.CrossRefGoogle Scholar
  45. 45.
    Byrn SR, Pfeiffer RR, Stowell JG (1999) Solid-State Chemistry of Drugs (2nd ed). SSCI, Inc., West Lafayette, Indiana.Google Scholar
  46. 46.
    Al-Mohizea AM; El-Bagory IM, Alsarra IA, Al-Jenoobi FI, Bayomi MA (2007) Effect of gamma radiation on the physicochemical properties of ciprofloxacin in solid state. J Drug Deliv Sci Technol 17:211–215.Google Scholar
  47. 47.
    Fitzpatrick S, McCabe JF, Petts CR, Booth SW (2002) Effect of moisture on polyvinylpyrrolidone in accelerated stability testing. Int J Pharm 246:143–151.CrossRefPubMedGoogle Scholar
  48. 48.
    Morris KR, Griesser UJ, Eckhardt CJ, Stowell JG (2001) Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes. Adv Drug Deliv Rev 48:91–114.CrossRefPubMedGoogle Scholar
  49. 49.
    Zhang GG, Law D, Schmitt EA, Qiu Y (2004) Phase transformation considerations during process development and manufacture of solid oral dosage forms. Adv Drug Deliv Rev 56:371–90.CrossRefPubMedGoogle Scholar
  50. 50.
    Swaminathan V, Kildsig DO (2002) Polydisperse powder mixtures: effect of particle size and shape on mixture stability. Drug Dev Ind Pharm 28:41–8.CrossRefPubMedGoogle Scholar
  51. 51.
    Reich G (2005) Near-infrared spectroscopy and imaging: basic principles and pharmaceutical applications. Adv Drug Deliv Rev 57:1109–1143.CrossRefPubMedGoogle Scholar
  52. 52.
    Vergote GJ, De Beer TRM, Vervaet C, Remon JP, Baeyens WRG, Diericx N, Verpoort F (2004) In-line monitoring of a pharmaceutical blending process using FT-Raman spectroscopy. Eur J Pharm Sci 21:479–485.CrossRefPubMedGoogle Scholar
  53. 53.
    Song M, de Villiers MM (2004) Changing the crystal form of a drug influences the affinity between the drug and a carrier when preparing interactive mixtures. Pharm Dev Technol 9:387–98.CrossRefPubMedGoogle Scholar
  54. 54.
    Planinsek O, Planinsek D, Zega A, Breznik M, Srcic S (2006) Surface analysis of powder binary mixtures with ATR FTIR spectroscopy. Int J Pharm 319:13–9.CrossRefPubMedGoogle Scholar
  55. 55.
    Gilani K, Najafabadi AR, Barghi M, Rafiee-Tehrani M (2005) The effect of water to ethanol feed ratio on physical properties and aerosolization behavior of spray dried cromolyn sodium particles. J Pharm Sci 94:1048–1059.CrossRefPubMedGoogle Scholar
  56. 56.
    Airaksinen S, Karjalainen M, Shevchenko A, Westermarck S, Leppanen E, Rantanen J,Yliruusi J (2005) Role of water in the physical stability of solid dosage formulations. J Pharm Sci 94:2147–2165.Google Scholar
  57. 57.
    Zhou GX, Ge Z, Dorwart J, Izzo B, Kukura J, Bicker G, Wyvratt J (2003) Determination and differentiation of surface and bound water in drug substances by near infrared spectroscopy. J Pharm Sci 92:1058–1065.CrossRefPubMedGoogle Scholar
  58. 58.
    Hausman DS, Cambron RT, Sakr A (2005) Application of on-line Raman spectroscopy for characterizing relationships between drug hydration state and tablet physical stability. Int J Pharm 299:19–33.CrossRefPubMedGoogle Scholar
  59. 59.
    Nokhodchi A, Javadzadeh Y (2007) The effect of storage condition on the physical stability of tablets. Pharm Technol Eur 19:January 1.Google Scholar
  60. 60.
    Zelkó R, Süvegh K (2004) Comparison of the enthalpy recovery and free volume of polyvinylpyrrolidone during anomalous glassy to rubbery transition. J Pharm Sci 21: 519–523.Google Scholar
  61. 61.
    FDA Guidance for Industry: ANDAs (2007) Pharmaceutical solid polymorphism chemistry, manufacturing, and controls information.Google Scholar
  62. 62.
    FDA Guidance for Industry (2002) Nasal spray and inhalation solution, suspension, and spray drug products – chemistry, manufacturing, and controls documentation.Google Scholar
  63. 63.
    Wong J, Papadopoulos P, Rebbeck C, Schwabe S, Lischewski G, Melchert J, Kuu W, Agostinelli T, Smith T, Brame G, Lynn R, Hepler D (2004) Effect of terminal sterilization by irradiation on amber Type I and Type III glass containers containing veterinary oxytetracycline suspension. PDA J Pharm Sci Technol 58:6–14.PubMedGoogle Scholar
  64. 64.
    Shamblin SL (2004) The role of water in physical transformations in freeze-dried products. Biotechnol Pharm Aspects 2 (Lyophilization of Biopharmaceuticals) 229–270.Google Scholar
  65. 65.
    Trissel LA, Zhang Y (2005) Physical and chemical stability of palonosetron hydrochloride with fluorouracil and with gemcitabine hydrochloride during simulated Y-site administration. Int J Pharm Compd 9:320–322.Google Scholar
  66. 66.
    Pearson JT, Varney G (1969) Crystal growth studies involving phase transition in aqueous drug suspensions. J Pharm Pharmacol 21:60S–69S.PubMedGoogle Scholar
  67. 67.
    FDA Guideline (1997) Nonsterile semisolid dosage forms. Scale-up and postapproval changes: chemistry, manufacturing, and controls; In vitro release testing and in vivo bioequivalence documentation.Google Scholar
  68. 68.
    Tiwary AK, Panpalia GM (1999) Influence of crystal habit on trimethoprim suspension formulation. Pharm Res 16:261–265.CrossRefPubMedGoogle Scholar
  69. 69.
    de Villiers MM, Mahlatji MD, Malan SF, van Tonder EC, Liebenberg W (2004) Physical transformation of niclosamide solvates in pharmaceutical suspensions determined by DSC and TG analysis. Pharmazie 59:534–540.Google Scholar
  70. 70.
    Müller RH, Jacobs C, Kayser O (2001) Nanosuspensions as particulate drug formulations in therapy rationale for development and what we can expect for the future. Adv Drug Deliv Rev 47:3–19.CrossRefPubMedGoogle Scholar
  71. 71.
    Rabinow BE (2004) Nanosuspension in drug delivery. Nat Rev Drug Discov 3:785–796.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Achaogen Inc.South San FranciscoUSA

Personalised recommendations